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Abstract Human antibodies specific for digoxigenin, estradiol, 
testosterone and progesterone have been isolated from a small 
combinatorial IgM repertoire (4 X10 7 ) of single chain antibodies 
(scFv). The affinities of both the anti-estradiol and anti-
progesterone scFv were approximately 108 M 1 . Naive IgM 
genes appeared to be highly represented, since only the heavy 
chain variable domain of the anti estradiol antibody contained 
differences to corresponding germline sequences. The light chain 
variable domain of the progesterone receptor was also identical 
to a germline sequence, showing that it is possible for completely 
naive antibodies to bind steroids with affinities comparable to 
those obtained after a secondary immune response. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Universal antibody libraries for the isolation of antibodies 
to any particular antigen have been generated by gene syn-
thesis using random sequences within the hypervariable re-
gions of the antigen binding site [1-7] or by randomly com-
bining the heavy and light chain variable domains of the 
antibody gene repertoire. Using this second approach, a hu-
man antibody library was generated containing at least 107 
members [8,9] from which antibodies were isolated to both 
small haptens and proteins including self-antigens [10,11] 
Their affinities were mainly in the micromolar range, similar 
to those obtained after a primary immune response. Theoret-
ically, it should be possible to select antibodies with affinities 
in the nanomolar range with a sufficiently large and diverse 
library [12]. Vaughan et al. [13] therefore created a human 
scFv antibody library consisting of 1.4 X 1010 clones from 
the human lymphocyte repertoire of naturally-rearranged V-
genes, including those derived from IgG. Antibodies with dis-
tinctly higher affinities could be isolated from this library. 
We recently described a set of primers for amplifying the 
antibody gene repertoire from human B lymphocytes based 
largely on available amino acid sequences [14]. Using these 
primers, we generated a single chain IgG antibody library 
from the lymphocytes of a patient with a high titer of auto-
antibodies to F(ab ' ) 2 fragments and isolated an ant i -F(ab ' ) 2 
scFv [15]. In the present investigation, we employed similar 
conditions to generate a small naive IgM antibody library. 
The hormones estradiol, testosterone and progesterone were 
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chosen as antigens for a first screening of this library, since 
they represent important clinical parameters and each of them 
shares either identical A and B rings or C and D rings with 
one of the other hormones, thus providing interesting compar-
isons of antibody specificity (Fig. 1). In addition, we included 
the steroid digoxigenin, which is a widely used marker. Hu-
man antibodies against this hapten are also useful for patient 
monitoring and provide potential therapeutic reagents for 
neutralising overdoses. To our knowledge, this is the first 
time that human antibodies to digoxigenin, testosterone and 
progesterone have been described. 
2. Materials and methods 
2.1. Antigens 
Digoxigenin-3-O-succinyl-e-aminocaproic acid-./V-hydroxy-succini-
mide ester (DIG-suc) and digoxigenin-3-O-methycarbonyl-E-amino-
caproic acid-^V-hydroxy-succinimide ester (DIG-met) were coupled 
to amino groups on BSA using a DIG-protein labeling kit from 
Boehringer, Mannheim, FRG. Digoxigenin-3-O-methylcarbonyl-
e-aminocaproyl-[5-(3-aminoallyl)-2'-desoxy-uridine-5'-triphosphate] 
(Dig-dUTP) was also obtained from Boehringer, Mannheim, FRG. 
The steroid hormones 17(3-estradiol-6-CMO-BSA (1,3,5-estratriene-
3,17p-diol-6-carboxymethyloxime: bovine serum albumin), testoster-
one-3-CMO-BSA (4-androsten-17(3-ol-3-one-3-carboxymethyloxime: 
BSA) and progesterone-3-CMO-BSA (4-pregnen-3,2O-dione-3-0-car-
boxymethyloxime: BSA) were supplied by Cortex Biochem (San 
Leandro, CA). 
2.2. Amplification of antibody genes 
Total RNA was prepared from the lymphocytes of twenty non-
immunized donors as previously described [16]. Messenger RNA 
was prepared using the Optiprep. 2 kit from Biometra (Gottingen, 
FRG) and transcribed into cDNA using a kit from Amersham ac-
cording to the manufacturer's instructions. The Fv-encoding regions 
of u, K and X chains were amplified by PCR using primers and con-
ditions similar to those described by Welschof et al. [14]. 
2.3. Phage display and selection for binding to antigen 
The naive IgM-derived library was displayed on phage as previ-
ously described for an IgG-derived library [15], The selection proce-
dure was performed using Maxisorb immunotubes (Nunc, Roskilde, 
Denmark) that had been coated with 125 ug of antigen conjugated to 
BSA and then blocked with 2% skimmed milk in PBS for 2 h at room 
temperature. 10n-1012 recomhinant phages that had been preab-
sorbed with 100 ug BSA in 2% skimmed milk in PBS for 1 h were 
used for the screening procedure. This was essentially performed as 
already described [15] and repeated three times. 
2.4. Phage-ELISA 
Microtiter plates were coated overnight with approximately 1 ug/ 
well of a given steroid-BSA conjugate or BSA. Following blocking 
with 2% (w/v) skimmed milk in PBS, between 109 and 1010 phages/ 
well were added and incubated for 1 h at room temperature. After 
washing five times with 0.1% Tween in PBS, 100 ul of the mouse 
monoclonal antibody FE2 [17] diluted 1:5000 was added and incu-
bated for 1 h at 37°C. After washing six times, the ELISA was de-
veloped with a monoclonal horseradish peroxidase (HRP) conjugated 
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goat-anti-mouse IgG antibody (Jackson ImmunoResearch Laboratory 
Inc., West Grove, PA) and the substrate 3,3',5,5'-tetramethylbenzi-
dine (TMB; Kierkegaard and Perry, Maryland, USA). The absorp-
tion was measured at 655 nm. 
2.5. Sequence analysis 
Nucleotide sequencing was performed using the dideoxy termina-
tion method with the vector pBluescript II SK(+) and specific primers. 
The sequences were analysed using a HUSAR sequence analysis pro-
gramme provided by the German Cancer Research Center and com-
pared with the EMBL data bank. 
2.6. Expression and purification of single chain antibodies in E. coli 
ScFv fragments were expressed in E. coli XLl-Blue (Stratagene) 
using the secretion vector pHOG21 [18]. Antibody fragments specific 
to estradiol, testosterone and progesterone were isolated from soluble 
periplasmic extracts and culture medium by immobilized metal affinity 
chromatography (IMAC) essentially as described [18]. ScFv fragments 
specific for digoxigenin were purified by IMAC followed by ion-ex-
change chromatography on a Mono S HR5/5 column (Pharmacia) as 
described [19]. Purified antibody fragments were dialyzed against 10 
mM HEPES, 0.15 M NaCl, 3.4 mM EDTA, 0.001% Tween 20, pH 
7.4 (HBS) for size-exclusion chromatography and affinity measure-
ments. The concentrations of scFvs were determined by both the 
Bradford dye-binding assay [20] using the Bio-Rad protein assay kit 
(Bio-Rad Laboratories, Munich, Germany) and spectrophotometri-
cally using the extinction coefficient elmg/ml = 1.66 for anti-digoxigenin 
scFv, 1.26 for anti-estradiol scFv, 1.47 for anti-testosterone scFv and 
1.44 for anti-progesterone scFv at 280 nm calculated according to Gill 
and von Hippel [21]. Analytical gel filtration of the scFv preparations 
was performed in HBS using a Superdex 75 HR10/30 column (Phar-
macia). Sample volume and flow rate were 200 jxl and 0.5 ml/min, 
respectively. A Low Molecular Weight Gel Filtration Calibration Kit 
(Pharmacia) was used to calibrate the column. The specificity of scFv 
preparations was analyzed by ELISA performed as previously de-
scribed [22]. 
2.7. Affinity measurements 
Antigen binding properties of scFv were characterized by surface 
plasmon resonance using a BIAcore 2000 instrument with a multi-
channel Integrated u-Fluidic Cartridge (Pharmacia Biosensor AB, 
Uppsala, Sweden). The antigens were immobilized using the amine 
coupling kit from the manufacturer at a concentration of 100 ug/ml 
in 10 mM sodium acetate buffer, pH 4.5. The flow cells of the sensor 
chips were loaded either with estradiol-BSA to give 1631 resonance 
units (RU; 1000 RU correspond to a surface concentration of 1 ng/ 
mm2), testosterone-BSA (1858 RU), progesterone-BSA (1220 RU) or 
digoxigenin-BSA (3564 RU for determination of association rates and 
572 RU for determination of dissociation rates). As a negative con-
trol, BSA was immobilized under the same conditions yielding 3562 
RU. One channel of each sensor chip was used after activation for 
injection of 10 mM sodium acetate buffer, pH 4.5, followed by deac-
tivation with ethanolamine. This channel was used to control the non-
specific binding of scFv to the carboxymethylated dextran surface. All 
the measurements were carried out at a flow rate of 5 ml/min in HBS 
at 25°C. After each cycle, the surface was regenerated by a single 5 |xl 
injection of 10 mM HC1. Analyses of scFv antibodies were performed 
in the concentration range 6.25-800 nM. Each injected sample of 
antibody fragment (25 ul) was in contact with the antigen for 5 
min. The dissociation was followed for 10 min. Kinetic constants 
were calculated using BIAevaluation 2.1 Software (Pharmacia Biosen-
sor AB). 
3. Results 
3.1. Library construction 
The cloning scheme for generating a library of scFv from 
the lymphocytes of healthy donors is outlined in Fig. 2. After 
amplifying the genes coding for the variable domains of the 
IgM heavy chains and kappa and lambda light chains with a 
set of primers that we described previously [14], the light chain 
repertoire was cloned into the phagemid display vector 
pSEX81 [15]. Sublibraries of approximately 2X107 members 
for the kappa and 1.5 X 107 for the lambda chains were ob-
tained. After combining them with the VH DNA repertoire, 
the library size was determined to be 4X107 after serial dilu-
tion followed by plating. 
3.2. Selection of antibodies to various steroids 
Digoxigenin and the steroid hormones estradiol, testoster-
one and progesterone coupled to free amino groups on BSA 
were immobilised on the walls of Nunc immunotubes for pan-
ning with the naive IgM-derived antibody library displayed on 
phagemid particles (see Experimental Protocol). A 1000-fold 
increase in the titer of binding phage was found after only the 
second round of screening against digoxigenin. The enrich-
ment of binding phage against the steroid hormones was 
more gradual but also quite significant after the third round. 
The specificity of clones isolated after the third round was 
checked by performing phage ELISAs. 
Five of six clones selected at random after the third round 
of screening for binding to digoxigenin were found to be iden-
tical (anti-DigA). The sixth clone (anti-DigB) was more spe-
cific, although equal numbers of phagemid particles carrying 
either of the two scFv showed similar binding to digoxigenin 
in a phage-ELISA (Fig. 3a). However, after expression of 
their DNA in E. coli, the affinities of the soluble scFv in 
periplasmic extracts were seen to be quite different. Extracts 
containing anti-DigA scFv bound less well than extracts con-
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Fig. 1. Construction of the naive IgM library. For details see the 
Methods in Section 2. 
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Fig. 2. Structural formulas of estradiol, testosterone, progesterone and digoxigenin. 
taining anti-DigB scFv, even though the anti-DigA scFv was 
present in significantly higher quantities (Fig. 3b). The higher 
affinity anti-DigB scFv reacted equally well with digoxigenin 
that was coupled to BSA using either of two different linkers. 
Furthermore, a soluble conjugate of digoxigenin coupled to 
dUTP was able to competitively inhibit its binding (Fig. 3c). 
To choose the best clones binding to estradiol, testosterone 
and progesterone, phage ELISAs of 100 randomly picked 
clones were performed. The DNA of fourteen anti-estradiol 
clones that appeared to bind best were found to be identical. 
In contrast, three different anti-testosterone clones were found 
amongst fourteen of the best binders. Of the 100 clones ana-
lysed for progesterone binding by phage ELISA, only two 
appeared to be specific. The most specific clones in each 
case were taken for further characterisation. 
3.3. Purification and characterisation of scFv 
Soluble scFv in periplasmic extracts were purified by metal 
chelate chromatography. Surprisingly, large variations were 
observed in the yield of purified scFv, ranging from 10.1 
mg/L for the anti-estradiol scFv to only 0.74 mg/L for the 
anti-progesterone scFv (Table 1). Analysis of the scFv prepa-
rations by size-exclusion chromatography demonstrated that 
scFv specific to digoxigenin, estradiol and testosterone con-
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Fig. 3. Binding of phage and scFv to digoxigenin as analyzed by ELISA. Anti-DigA and anti-DigB are two different clones selected by phage 
display, (a) Binding of phages to digoxigenin and steroid hormones coupled to BSA. Digoxigenin was coupled to BSA with a methylcarbonyl 
type linker, (b) Binding of scFv (periplasmic extract) to digoxigenin coupled by a methylcarbonyl (Dig-Met) or succinyl (Dig-Suc) type linker 
to BSA. The insert is a Western blot of anti-DigA (A) and anti-DigB (B) using equal amounts of extract, (c) Competitive inhibition of scFv 
(periplasmic extract) binding to Dig-Met by a soluble Dig-dUTP conjugate. 
sisted only of monomers while around 40% of the anti-pro-
gesterone scFv consisted of non-covalent dimers (data not 
shown). The purified antibody fragments interacted specifi-
cally with their target antigens as demonstrated by ELISA 
(Fig. 4) and BIAcore measurements (data not shown). The 
affinity constants calculated on the basis of real time anti-
body-antigen interaction analysis were quite high for antibod-
ies from a naive library (Table 1). 
A sequence analysis of these antibodies showed that the 
genes coding for the VH domain of the anti-steroid hormones 
and anti-DigA, the low affinity anti-digoxogenin scFv, all be-
longed to the same family, namely, DP47, whereas that of 
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Fig. 4. Binding of purified anti-estradiol scFv, anti-testosterone scFv 
and anti-progesterone scFv at concentrations of 10 ug/ml to differ-
ent antigens as analyzed by ELISA. 
anti-DigB, the high affinity anti-digoxigenin scFv, belonged to 
DP71 (Table 2). Four of the five VH gene sequences showed 
no differences at all to the germline sequences from which 
they were derived. These results suggest that the primers 
and conditions used for amplifying the repertoire of naive 
IgM genes were well chosen. All the light chains on the other 
hand showed significant sequence differences to the nearest 
germline sequence. 
4. Discussion 
4.1. Antibody library 
Our IgM-derived antibody library contained 4 XlO7 inde-
pendent clones. Four of the five sequenced VH clones de-
scribed in Table 2 are completely homologous to known 
germline sequences, indicating that the naive IgM repertoire 
was indeed highly represented. In comparison, none of the 
published VH sequences from a much larger lymphocyte-de-
rived library containing 1.4 X1010 members was completely 
homologous to a germline sequence [13]. The explanation 
could lie in the choice of antisense primers, which in the latter 
investigation were homologous to four JH regions for ampli-
fying DNA coding for all the VH domains. However, most of 
the clones from a similarly derived library using IgM-specific 
primers for cDNA synthesis also contained a significant num-
ber of differences to the nearest germline sequence [9]. Possible 
explanations put forward by the authors were that somatic 
mutation was occurring prior to the clonal expansion of spe-
cific B cells or mutations were being introduced by PCR. The 
differences between the light chains and nearest germline se-
quences possibly reflect larger quantities of mRNA from ma-
ture versus immature B cells, since it was not possible to 
discriminate between these populations. 
4.2. Antibody affinities 
Considering the small size of the present library and the use 
of VH domains that have not been matured by somatic muta-
tion, the equilibrium association constants of the antibodies to 
digoxigenin, estradiol, testosterone and progesterone shown in 
Table 1 are quite high, approaching the affinities that one 
would only expect from a secondary immune response. Both 
the anti-estradiol and anti-progesterone clones, for example, 
have association constants of 1.0X108 M—1 and 1.3XlO8 
M—1, respectively. For comparison, a value of 6XlO8 M"1 
was recently obtained for a human scFv to estradiol that had 
been selected from the library of 1010 clones mentioned above 
and then reshuffled to increase its affinity [23]. Moreover, its 
rate of dissociation (2XlO- 3 s - 1) , which is particularly im-
portant for the stability of binding, was not lower than that of 
our anti-estradiol scFv. The anti-estradiol antibody described 
here also appeared to be quite specific for its antigen, in con-
trast to the anti-progesterone antibody that showed a small 
amount of cross-reactivity with estradiol and testosterone. 
To our knowledge, no other human anti-progesterone anti-
bodies have been described. Murine anti-progesterone anti-
bodies isolated from a naive IgM library of 5 X 106 members 
by phage display of Fab fragments fused to the major coat 
protein pVIII had affinities of 104—105 M _ 1 , in the range ex-
pected for a primary response [24]. One reason for the lack of 
binders postulated by the authors was the possible absence of 
particular subgroups in their library, since all or most of the 
anti-progesterone monoclonal antibodies are encoded by a VH 
gene from the small and infrequently used VGAM3.8 family 
and VL genes from the VK5.1 gene of the VKII subgroup [25-
27]. In contrast, the genes coding for our anti-progesterone 
antibody belong to commonly used families and the VH gene 
DP47, in particular, is one of the most frequently found when 
screening antibody libraries with haptens [5,13]. The affinities 
Table 1 
Production levels and kinetic parameters for binding of anti-steroid scFvs to their antigens as measured by the BIAcore 2000 system 
scFv 
anti-Est 
anti-Test 
anti-Dig 
anti-Prog 
Valency" 
M 
M 
M 
M+D 
Yieldb 
(mg/1 of culture) 
10.1 
4.3 
0.84 
0.74 
•^on 
(ivr1 s^1 s^ 1) 
(1.78 ±0.04) XlO5 
(1.06 ±0.11) XlO5 
(4.00±0.80)XlO4 d 
(1.16±0.08)X105 
koii 
(1.78 ±0.64) XlO"3 
(1.96 ±0.36) XlO"3 
(3.48±0.63)XlO"3 e 
(8.68 ±0.48) XlO"4 
-"a — f^on'^ott 
(M-1) 
l.oi xio8 
5.41 XlO7 
1.15X107 
1.34 XlO8 
aM, monomers; D, dimers. 
bAfter purification. 
"Affinity (equilibrium association) constants obtained directly from the ratio k0Jk0g. 
dKinetic association rate constants obtained using immobilized 3564 RU of Dig-BSA. 
eKinetic dissociation rate constants obtained using immobilized 572 RU of Dig-BSA. 
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Table 2 
Sequences of anti-steroid antibody variable domains 
scFv Family Germline gene Amino acids differences from germline" CDR3 aa sequence 
(A) Heavy chains 
anti-DigA 
anti-DigB 
anti-Est 
anti-Prog 
anti-Test 
(B) Light chains 
anti-DigA 
anti-DigB 
anti-Est 
anti-Prog 
anti-Test 
VH3 
VH4 
VH3 
VH3 
VH3 
VL1 
VL1 
VL3 
VL2 
VL2 
DP-47 
DP-71 
DP-47 
DP-47 
DP-47 
DPL-3 
DPL-3 
DPL-16 
LV2018 
DPL-12 
0 
0 
5 
0 
0 
4 
14 
8 
0 
9 
D KGSGWY 
VSS RGVDP 
DLGYYGSGSQPFEY 
-WLRG LNYFDY 
DWR VVPAD 
AAWDDS--LSGVV 
ASWDES--LTGVV 
NSRDRSGNHVNVL 
SSYTRT--STRVL 
SSYAGR--NSFYV 
"Excluding the primer region. 
Human germline segments have been assigned according to the V-BASE Sequence Directory, Tomlinson et al., MRC Centre for Protein Engineer-
ing, Cambridge, UK. 
The nucleotide sequences have been submitted to the EMBL-Data Bank with the following accession numbers: anti-DigA X98751(VH), 
X98752(VL); anti-DigB X98749(VH), X98750(VL); anti-Est Y09384(VH), Y09385(VL); anti-Test Y09386(VH), Y09387(VL). 
of the secondary response murine monoclonal antibodies 
range from 2-5 XlO8 M _ 1 , which are not much higher than 
the affinity of the human anti-progesterone antibody de-
scribed in this paper. In particular, the anti-progesterone anti-
body had a low dissociation rate constant of 8.7 X 10~4 M _ 1 , 
probably reflecting to some extent the presence of scFv 
dimers. The other scFvs were present exclusively as mono-
mers, thus demonstrating that avidity effects played no part 
in their relatively high affinity binding. 
The affinity of the anti-testosterone antibody was about five 
times lower than those of the antibodies to estradiol and pro-
gesterone. Other human antibodies to testosterone have not 
yet been described. An ELISA of the purified scFv showed 
little cross-reactivity with either estradiol or progesterone, 
which is surprising considering that one end of the molecule 
resembles estradiol and the other end progesterone. Indeed, 
the only difference between testosterone and progesterone is at 
position 17, which is at the end furthest away from the linker 
joining position 3 to BSA. This is a strong indication that the 
linker makes no contribution to antibody binding. Similarly, 
the absence of any significant cross-reactivity of the estradiol 
antibody with the other steroids suggests that the carboxy-
methyloxime linker makes no contribution to binding. 
The anti-digoxigenin scFv (anti-DigB) bound equally well 
to digoxigenin coupled with either one of two different linkers 
to BSA. Furthermore, this binding could be competitively 
inhibited by using a soluble conjugate of digoxigenin coupled 
to dUTP. The antibody anti-DigA bound digoxigenin with a 
much lower affinity, although equal numbers of phage par-
ticles carrying the genes for either anti-DigA or anti-DigB 
gave similar ELISA readings. The reason for this apparent 
contradiction appears to be the higher amount of soluble 
functional anti-DigA produced by E. coli. The concentration 
of phage particles carrying anti-DigA is therefore probably 
higher than those carrying anti-DigB. A fraction of the phage 
might also be carrying more than one anti-DigA antibody, 
which would increase the avidity of binding. 
Interestingly, the first single chain antibody was engineered 
using the VH and VL domains of the murine anti-digoxin 
monoclonal antibody 26-10 [28]. It was expressed in E. coli 
and refolded from inclusion bodies. More recently, another 
high affinity murine anti-digoxin scFv with more specific bind-
ing characteristics was isolated in a soluble form from the 
periplasm of E. coli [29]. Both antibodies cross-reacted with 
the very similar digoxigenin. Human antibodies against digox-
in and its active metabolites are particularly interesting be-
cause of their potential clinical application for treating over-
doses of this widely prescribed heart stimulant. To our 
knowledge, this is the only report until now of a human 
anti-digoxigenin antibody. 
4.3. Yields of soluble scFv 
A pure preparation of the anti-estradiol scFv was obtained 
at the relatively high yield, for shake flask cultures, of approx-
imately 10 mg/L. In contrast, the yield of the anti-progester-
one antibody was only 0.74 mg/L. Similar variations have 
been observed in the yields of other recombinant antibodies 
[18,19,30,31]. In E. coli, the secretion machinery directs the 
recombinant scFv proteins to the periplasm where the degree 
of successful folding appears to depend largely on the primary 
structure [32,33]. The sequence of the anti-estradiol scFv 
might therefore provide a suitable framework for humanising 
murine antibodies or for generating synthetic human antibody 
libraries. 
The VH domain of the estradiol antibody and of the other 
antibodies with the exception of anti-DigB are derived from 
DP47, a germline sequence that is often found after selection 
by phage display (see above). This frequent occurrence may 
depend to some extent on the efficiency of folding. When 
paired with a light chain that also folds efficiently, high levels 
of soluble scFv would be secreted, as in the case of the anti-
estradiol and anti-DigA antibodies. 
In conclusion, we have obtained human anti-steroid scFv 
from a relatively small IgM-derived library with affinities sim-
ilar to those obtained after a secondary immune response. 
Most of the VH genes were identical to germline sequences. 
The anti-progesterone scFv was composed of VH and VL do-
mains that were both identical to germline sequences, showing 
that completely naive VH/VL combinations can bind steroids 
with relatively high affinity. 
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